Photopic full-field electroretinography and optical coherence tomography in type 1 diabetic retinopathy by unknown
RETINAL DISORDERS
Photopic full-field electroretinography and optical coherence
tomography in type 1 diabetic retinopathy
Ragnhild Wivestad Jansson1,2 & Maria Baroy Raeder3 & Jørgen Krohn1,2
Received: 20 November 2014 /Revised: 6 April 2015 /Accepted: 22 April 2015 /Published online: 26 May 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract
Purpose The purpose of this study was to evaluate the role of
photopic full-field electroretinography (ERG) and retinal
thickness measurements by spectral-domain optical coherence
tomography (SD-OCT) in the assessment of disease severity
in type 1 diabetic retinopathy.
Methods A population-based cohort of 151 patients with type
1 diabetes underwent a complete ophthalmic examination,
including photopic full-field ERG and SD-OCT for retinal
thickness measurements. Stereoscopic fundus photographs
were taken according to the Early Treatment Diabetic
Retinopathy Study protocol, and the classification of diabetic
retinopathy was based on the International Clinical Diabetic
Retinopathy Disease Severity Scale. Associations between
photographically determined retinopathy level, b-wave ampli-
tude and peak time of the photopic single-flash and 30-Hz
flicker ERG, and central retinal thickness parameters were
evaluated.
Results For all ERG measurements, the amplitude decreased
and peak time increased with progression of the disease, but
these associations lost statistical significance after adjusting
for age and excluding laser-treated patients. Mean retinal
thickness was significantly associated with the b-wave ampli-
tude of photopic single-flash and 30-Hz flicker responses (r2=
0.08, p=0.006; and r2=0.05, p=0.025, respectively), but re-
vealed no association with retinopathy level.
Conclusions Photopic full-field ERG and SD-OCT-derived
retinal thickness parameters have limited clinical value in the
staging of diabetic retinopathy. However, thinning of the cen-
tral retina leads to significant functional impairment and may
reflect an ongoing neurodegenerative process in the retinal
tissue.
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Introduction
The global prevalence of diabetes mellitus has been rapidly
increasing, and it has become a disease of epidemic propor-
tions [1]. Despite significant advances in medical and surgical
management, diabetic retinopathy remains one of the most
frequent and serious complications of diabetes. These trends
necessitate early diagnosis and improved monitoring of ocular
disease in order to optimize patient care and to reduce the
burden of illness on patients and society. Assessment of retinal
vascular changes, either by ophthalmoscopy or fundus pho-
tography, has traditionally been used to determine the severity
of diabetic retinopathy [2–4]. However, several studies have
shown that neuronal cell death, apoptosis, and retinal dysfunc-
tion may occur before microvascular disease can be detect-
ed [5, 6], and it is still unclear whether the retinal neurop-
athy is the result of diabetic microangiopathy, direct neu-
rological damage from chronic hyperglycaemia, or both
[7, 8].
Full-field electroretinography (ERG) is a non-invasive
technique for evaluating global retinal function and is
* Ragnhild Wivestad Jansson
ragnhild.wivestad.jansson@helse-bergen.no
1 Department of Clinical Medicine, Section of Ophthalmology,
University of Bergen, Bergen, Norway
2 Department of Ophthalmology, Haukeland University Hospital,
5021 Bergen, Norway
3 Department of Gynecology and Obstetrics, Haukeland University
Hospital, Bergen, Norway
Graefes Arch Clin Exp Ophthalmol (2015) 253:989–997
DOI 10.1007/s00417-015-3034-y
recognized as an important clinical tool for understanding the
pathology of acquired retinal diseases [9, 10]. Full-field ERG
studies in patients with diabetes have demonstrated a wide
variety of changes associated with the severity of retinopathy
[11]. One of the earliest signs of diabetic retinopathy, some-
times even preceding the vascular changes, is a reduction in
the amplitude and an increase in the peak time (implicit time)
of the oscillatory potentials [12, 13]. The summed amplitudes
of the oscillatory potentials have been considered the most
sensitive prognostic marker of progression to proliferative di-
abetic retinopathy [11, 14, 15]. A reduction in amplitude and
delayed peak time of the b-wave in single-flash and 30-Hz
flicker ERG have also been identified as significant markers
of diabetic retinopathy, but are associated with more advanced
disease [11, 16]. A few studies have evaluated photopic ERG
responses in diabetic eyes. Holopigian et al. and Bresnick and
Palta demonstrated that the peak time of photopic 30-Hz
flicker ERG correlated significantly with the severity of
diabetic retinopathy [17, 18]. Similarly, using photopic
single-flash ERG, Satoh et al. found a delayed peak
time and reduced b-wave amplitude, noting that peak
time showed the highest association with progression
of retinopathy [19].
Spectral domain optical coherence tomography (SD-
OCT) is another non-invasive technique that has now
become a standard method for diagnosing and monitor-
ing diabetic macular oedema. Previous optical coherence
tomography studies have shown inconsistent results re-
garding retinal morphological changes in diabetes pa-
tients, as some researchers have reported an increase
[20–23] whereas others have reported a decrease in cen-
tral retinal thickness [24–27]. Recent evidence suggests
that selective thinning of the inner retinal layers takes
place during the earliest stages of diabetic retinopathy,
supporting the view that diabetic retinopathy is also a
neurodegenerative disorder [7, 28].
Both photopic full-field ERG and SD-OCT are accu-
rate, objective and readily available methods for
assessing retinal function and morphology that may be
useful in the clinical management of patients with dia-
betic retinopathy. However, results from previous studies
are conflicting, study populations were heterogeneous,
and most research has focused on differences between
non-diabetic and diabetic subjects. Thus, the clinical
value of different full-field ERG responses and retinal
thickness measurements as markers of disease staging
and progression are still unclear.
The main objectives of the present study were to examine
the relationships between different stages of diabetic retinop-
athy assessed by fundus photography, various photopic full-
field ERG parameters, and SD-OCT-derived retinal thickness




Haukeland University Hospital is a tertiary care centre situated
in the county of Hordaland, which has a population of about a
half-million inhabitants (Statistics Norway 2013). Patients
with type 1 diabetes mellitus were identified through a search,
using the International Classification of Diseases (ICD) diag-
nosis codes for type 1 diabetes (E10 and all its subcategories),
of the databases of hospitals, endocrinologists, and a selection
of general practitioners in our region with a special interest in
diabetes. The search identified 5545 patients, of whom a ran-
dom sample of 1200 medical records were reviewed in order
to exclude incorrectly diagnosed patients and those who were
not residents of Hordaland County. This resulted in a random-
ly selected cohort of 350 patients with serological evidence of
autoimmune type 1 diabetes. By the end of December 2013,
210 of these patients had been recruited for an ongoing epide-
miological study on the prevalence and severity of diabetic
retinopathy in Western Norway. Among these patients, those
aged 17 years or older were asked to participate in the present
ERG and SD-OCT study. Patients with retinal or optic nerve
diseases other than diabetic retinopathy or media opacities
leading to ungradable images and scans were excluded.
The study was registered and approved by the Regional
Committee for Medical and Health Research Ethics, Western
Norway, and followed the official ethical regulations for clin-
ical research and the Declaration of Helsinki. All patients gave
their written informed consent prior to participation in the
study.
Ophthalmologic examination, fundus photography,
and classification of diabetic retinopathy
Information regarding patient demographics and medical his-
tory was collected from the medical records. All study partic-
ipants underwent a detailed eye examination, with assessment
of best-corrected visual acuity, measurement of intraocular
pressure by Goldmann applanation tonometry, and slit lamp
examination. Following pupil dilation with topical
tropicamide (0.5 %) and phenylephrine hydrochloride
(10 %), indirect ophthalmoscopy was performed with a 90-
dioptre lens. Fundus photography was performed by an expe-
rienced ophthalmic photographer using the Canon CF-60Dsi
digital fundus camera system combined with a Canon EOS-
1D Mark II camera (Canon, Inc., Tokyo, Japan). The level of
diabetic retinopathy was determined from stereoscopic colour
fundus photographs with 40° fields of view that were taken of
the seven standard fields according to the Early Treatment
Diabetic Retinopathy Study (ETDRS) protocol [29]. In addi-
tion, a total of five red-free photographs with 60° fields of
view were taken, as follows: centred on the macula, temporal
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to the macula, nasal to the optic disc, superior to the optic disc,
and inferior to the optic disc. The colour fundus images were
displayed on a calibrated LCD monitor and assessed with a
handheld stereoscopic viewer (ScreenScope; Stereo Aids,
Albany, Australia). All images were reviewed and graded by
two retina specialists (RJ and JK), who were masked to other
patient information. The level of diabetic retinopathy was
graded according to the International Clinical Diabetic
Retinopathy Disease Severity Scale: 1 = no retinopathy; 2 =
mild non-proliferative retinopathy; 3 = moderate non-
proliferative retinopathy; 4 = severe non-proliferative retinop-
athy; 5 = proliferative retinopathy [4]. Levels 1, 2, and 3
represent relatively low risk of visual loss, while levels 4
and 5 represent significant risk [4]. In the case of discrepancy,
the fundus images were discussed by the two graders until
mutual agreement was reached. Macular oedema was classi-
fied as either present or absent based on the presence of retinal
thickening or hard exudates in the posterior pole [4].
Electroretinography
After pharmacological pupil dilatation, light-adapted
(photopic) full-field electroretinograms were recorded in both
eyes using a Nicolet Viking IV D analysis system (Nicolet
Biomedical Instruments, Madison, WI, USA). A Burian–
Allen bipolar contact lens electrode was applied on the topi-
cally anaesthetized cornea (oxybuprocaine hydrochloride
0.4 %) and a ground electrode was placed on the patient’s
forehead. Recordings were made in accordance with the stan-
dards of the In te rna t iona l Soc ie ty fo r Cl in ica l
Electrophysiology of Vision (ISCEV) [30]. Photopic re-
sponses (background illumination intensity = 34 cd/m2) were
obtained with a wide-band filter (−3 dB at 1 Hz and 500 Hz)
stimulating with single full-field flashes of white light (inte-
grated luminance 3.93 cd.s/m2), and cone responses were ob-
tained with 30-Hz flickering white light (integrated luminance
0.81 cd.s/m2) averaged from 20 sweeps. Recordings of both
ERG measurements were repeated until two identical curves
were obtained in order to ensure reproducibility. The b-wave
amplitude and peak time were measured in both photopic
single-flash and 30-Hz flicker ERG.
Optical coherence tomography
All patients underwent SD-OCT imaging in both eyes through
dilated pupils using the spectral domain Topcon 3D OCT-
1000 Mark II (software version 3.51; Topcon Corp., Tokyo,
Japan). SD-OCT scanning was performed by an experienced
ophthalmic photographer. The protocol used for all eyes was a
3Dmacula scan based on a 6×6 mm rectangular scan area and
512×128 lines (128 horizontal scan lines comprising 512 A-
scans), and an axial resolution of 6 μm. The central foveal
thickness, mean retinal thickness, and total macular volume
corresponding to the nine subfields of the 6-mm-diameter
ETDRS macular grid were calculated [31]. Eyes with
decentred SD-OCT scans were excluded.
Statistical analysis
Two sets of analyses were conducted, one including and one
excluding patients who had previously received laser treat-
ment for diabetic retinopathy. We used one-way analysis of
variance (ANOVA) statistics to evaluate the association be-
tween the five levels of retinopathy and the ERG and SD-
OCT findings. Post hoc ANOVA testing was performed using
Bonferroni’s multiple comparison test. The data were adjusted
for age by analysis of covariance (ANCOVA). Simple linear
regression was used to model the associations between ERG
and SD-OCT measurements. The upper and lower limits of
normal values were defined as the mean plus and minus two
standard deviations, respectively. Comparison of two means
was performed using the unpaired two-tailed t test. The level
of interobserver agreement was estimated by Cohen’s kappa
statistics. The data were analysed using Stata version 13.0
software (StataCorp LP, College Station, TX, USA). For all
tests, two-tailed p values<0.05 were considered statistically
significant.
Results
Patients and fundus photography
The majority of the patients included in the epidemiologic
study of diabetic retinopathy in Western Norway agreed to
participate in the present ERG and SD-OCT study. Thus the
study was performed in a randomly selected, population-
based cohort of mainly adult patients with type 1 diabetes
from the western part of Norway. The study included a total
of 151 patients, of whom 71(47 %) were women and 80
(53 %) were men. The median age at the time of examination
was 36 years (range, 17–74 years). One of the seven patients
with severe non-proliferative diabetic retinopathy (level 4)
and 18 of the 20 patients classified as having proliferative
diabetic retinopathy (level 5) had previously undergone
panretinal photocoagulation in both eyes. Patient demo-
graphics according to the levels of retinopathy are presented
in Table 1.
Photographically determined macular oedema was present
in nine (6 %) patients (three female, six male) with a median
age of 34 years (range, 21–49 years). Two patients had level 2,
three had level 3, two had level 4, and two had level 5 diabetic
retinopathy. In the majority of these patients, focal retinal
thickening and hard exudates were seen in the parafoveal or
extrafoveal regions. The patients with macular oedema had a
mean central foveal thickness of 236 μm (range, 207–
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290 μm) and mean retinal thickness of 267 μm (range, 242–
307 μm). Compared to the rest of the study population,
they had significantly greater central foveal thickness
(p=0.02), while there was no significant difference in
mean retinal thickness (p=0.82).
The colour and red-free fundus photographs were of good
diagnostic quality, allowing assessment of the level of diabetic
retinopathy with a high degree of accuracy. The Cohen’s kap-
pa value for agreement between the two graders was 0.92.
Association between ERGparameters and level of diabetic
retinopathy
A total of 151 patients were examined with photopic 30-Hz
flicker ERG, and photopic single-flash responses were also
obtained in 124 of these patients. All ERG responses of the
right and left eyes were highly correlated, as exemplified in
the scatter plot of Fig. 1 showing the correlation in 30-Hz
flicker peak time between right and left eyes (r2=0.83,
p<0.0001). As such, only the right eyes were used for further
analysis in this study.
When all patients were included in the analysis, there was a
negative association between retinopathy severity level and the
b-wave amplitude of both the photopic single-flash and 30-Hz
flicker responses. These associations remained statistically sig-
nificant after adjusting for age (r2=0.43, p<0.001; and r2=0.35,
p<0.001, respectively). There was also a gradual prolongation
of the b-wave peak time with increasing severity of diabetic
retinopathy in the photopic single-flash and 30-Hz flicker ERG,
which maintained statistical significance after adjusting for age
(r2=0.22, p=0.009; and r2=0.48, p<0.001, respectively).
When the patients who had undergone panretinal photoco-
agulation were excluded from the analysis (n=19), there was a
similar trend towards decreasing amplitudes and increasing
peak time with more advanced retinopathy. For patients in the
20–50-year age group (representing 82 % of patients), the low-
er limit of normal single-flash b-wave amplitude was 73.7 μV
and the upper limit of normal 30-Hz flicker peak time was
28.4 ms. Box plots illustrating the association (after exclusion
of laser-treated patients) between the diabetic retinopathy level
and single-flash b-wave amplitude, and between the retinopa-
thy level and 30-Hz flicker peak time, are shown in Figs. 2 and
3, respectively. After adjusting for age, these associations were
not statistically significant for either the b-wave amplitude of
the photopic single-flash (r2=0.19, p=0.59) and 30-Hz flicker
(r2=0.11, p=0.82) responses or the b-wave peak time of the
photopic single-flash (r2=0.13, p=0.16) and 30-Hz flicker (r2=
0.27, p=0.32) responses. When the analyses were performed
without the outliers indicated in Figs. 2 and 3, only the associ-
ation between retinopathy level and 30-Hz flicker peak time
became statistically significant (r2=0.35, p=0.03). All other
associations remained non-significant.
Mean ERG parameters and standard deviations for all pa-
tients and within each group of patients at a given retinopathy
level are listed in Table 2.
Association between SD-OCT parameters and level
of diabetic retinopathy
All 151 patients were examined using SD-OCT. As the mean
retinal thickness and mean macular volume were almost
Table 1 Patient demographics according to severity level of diabetic retinopathy
Variable All patients Patients grouped by level of diabetic retinopathy
1 2 3 4 5
Females, n (%) 71 (47) 28 (51) 20 (44) 11 (46) 2 (29) 10 (50)
Males, n (%) 80 (53) 27 (49) 25 (56) 13 (54) 5 (71) 10 (50)
Age at examination, years, median (range) 36 (17–74) 30 (17–59) 36 (19–58) 41 (21–74) 39 (31–54) 46 (34–70)
Duration of diabetes, years, median (range) 17 (0–63) 10 (0–38) 17 (4–46) 23 (10–63) 29 (21–34) 33 (18–60)
Fig. 1 Scatter plot showing the high correlation between the 30-Hz
flicker peak time measured in the right and left eyes of each subject
(r2=0.83, p<0.0001)
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perfectly correlated (r2=0.99, p<0.001), we decided to focus
on the central foveal thickness and mean retinal thickness, as
described in the following analysis. Similar to the ERG data,
the central foveal thickness and mean retinal thickness in the
right and left eyes of patients showed highly significant cor-
relations (r2=0.45, p<0.001; and r2=0.71, p<0.001, respec-
tively), and we therefore used only the SD-OCT data obtained
from the right eye of all subjects for further analysis.
There was no statistically significant association between
retinopathy severity levels and retinal thickness parameters,
regardless of whether the data were age-adjusted. After
adjusting for age, no significant association was found be-
tween the level of retinopathy and central foveal thickness or
mean retinal thickness, either when the laser-treated patients
were included in the analysis (r2=0.03, p=0.54; and r2=0.03,
p=0.79, respectively) or when they were excluded (r2=0.03,
p=0.63; and r2=0.03, p=0.48, respectively). Similarly,
excluding the nine patients with macular oedema from the
analysis did not significantly affect these results. The relation-
ship between the retinopathy severity level and mean retinal
thickness (when laser-treated patients are excluded) is illus-
trated in Fig. 4. Mean SD-OCT parameters and standard de-
viations for all patients and within each group of patients at a
given retinopathy level are listed in Table 2.
Association between ERG and SD-OCT parameters
Among patients who underwent both ERG and SD-OCT ex-
aminations, and after age adjustment and exclusion of those
who had received panretinal photocoagulation, there was a
significant association between SD-OCT-derived mean retinal
thickness and the b-wave amplitudes of photopic single-flash
and 30-Hz flicker responses (r2=0.08, p=0.006; and r2=0.05,
p=0.025, respectively). There was also a gradual prolongation
of the peak time with reduction of retinal thickness, indicating
a weak negative association between the mean retinal thick-
ness and the peak time of the 30-Hz flicker responses (r2=
0.03, p=0.068). There was no association between the mean
retinal thickness and peak time of the single-flash responses
(r2=0.002, p=0.724) or between the central foveal thickness
and any of the ERG parameters. Scatter plots illustrating the
associations between mean retinal thickness and the various
ERG parameters are shown in Fig. 5.
Discussion
The gold standard for the detection and grading of diabetic
retinopathy has traditionally been retinal examination by indi-
rect ophthalmoscopy or 7-field stereoscopic photographs of
each eye as defined by the ETDRS [29]. In light of current
concepts of neurodegeneration in the pathogenesis of diabetic
retinopathy, additional diagnostic tools like ERG and SD-
OCT may also be of value in the management of the disease.
In the present study, we investigated possible associations
between photographically determined retinopathy levels, var-
ious photopic ERG parameters, and central retinal thickness
measurements assessed by SD-OCT. As would be expected in
a population-based analysis of diabetes complications, there
were substantial variations in age, diabetes duration, and sam-
ple size among the five levels of disease severity. The distri-
bution of retinopathy severity levels and the frequency of
macular oedema among patients largely corresponded with
that found in other studies [32–34].
The patients with macular oedema had greater central fo-
veal thickness compared to the rest of the study population.
There was no significant difference in mean retinal thickness,
which may have been due to the fact that the oedema in most
cases presented as a small area of focal retinal thickening in
the parafoveal or extrafoveal regions. Macular oedema was
Fig. 2 Box plot of the single-flash b-wave amplitude grouped according
to the level of diabetic retinopathy, excluding laser-treated patients.
Middle line: the median; bottom and top box edges: the 25th and 75th
percentiles; whiskers: the most extreme values within 1.5 interquartile
ranges; dots: outliers
Fig. 3 Box plot of the 30-Hz flicker peak time grouped according to the
level of diabetic retinopathy, excluding laser-treated patients. Box plot
details are as described in Fig. 2
Graefes Arch Clin Exp Ophthalmol (2015) 253:989–997 993
determined from stereoscopic fundus photographs and was
based on the presence of retinal thickening or hard exudates
in the posterior pole [4]. This method is not without limita-
tions [35], and as such, some patients with macular oedema
may have been missed. While ophthalmoscopy or stereoscop-
ic fundus photography is still recommended for routine diag-
nosis of diabetic macular oedema, the use of SD-OCT is in-
creasing, and it is regarded by many as the new reference
standard [35].
In order to determine the correct stage and to detect the
most subtle changes in diabetic retinopathy, such as the first
appearance of microaneurysms, intraretinal microvascular ab-
normalities (IRMA), or neovascularization, the stereoscopic
colour photographs were compared to the red-free fundus im-
ages [36]. This approach of analysing both colour and red-free
fundus photographs based on the International Clinical
Diabetic Retinopathy Disease Severity Scale [4] led to a high
degree of interobserver agreement in the assessment of reti-
nopathy severity level.
The primary analysis of the cohort showed a clear trend of
decreasing b-wave amplitude and increasing 30-Hz flicker
peak time with the progression of retinopathy, and these asso-
ciations remained statistically significant after age adjustment.
Both the prevalence and severity of diabetic retinopathy cor-
relate with age [37], and previous studies have shown that
amplitudes decline and peak times increase with ageing [38,
39]. Although the ageing effect on these ERG parameters is
relatively small, it must be taken into account, as patient age
and severity of diabetic retinopathy are so closely interrelated.
In addition, laser treatment has an attenuating effect on ERG
parameters. Previous studies have shown a marked reduction
in the amplitude of both a- and b-waves and a delay in b-wave
peak time after panretinal laser treatment [17, 40, 41]. Thus,
ageing and laser treatment have a synergistic negative influ-
ence on ERG response.When the patients who had previously
undergone panretinal photocoagulation were excluded from
the analyses, the age-adjusted associations between retinopa-
thy level and ERG results were no longer statistically signifi-
cant. Some of the earlier studies that reported significant full-
field ERG changes in diabetes patients had included the addi-
tional performance of fluorescein angiography [16–18], which
may have the advantage of more precise retinopathy staging.
In the present study, however, we analysed a large population-
based cohort of randomly selected patients with type 1 diabe-
tes and performed detailed age-adjusted ERG analyses among
five severity levels of diabetic retinopathy, and we believe that
these differences in patient selection and statistical methods
contributed to the discrepancy between our findings and those
that have been reported by others.
We found no obvious association between the severity of
diabetic retinopathy and any of the SD-OCT-derived retinal
thickness measurements. The morphological parameters
remained stable across all retinopathy levels regardless of
whether the laser-treated patients were included in the analy-
sis. Panretinal photocoagulation, however, has been shown to
induce retinal thickening in both the peripapillary and macular
Table 2 ERG results and SD-OCT findings according to the severity level of diabetic retinopathy. All data are presented as mean±standard deviation
(SD), with the number of patients (n) in parentheses
Variable All patients Patients grouped by level of diabetic retinopathy
1 2 3 4 5
Single-flash ERG,
b-wave amplitude, μV
149.1±59.8 (n=124) 174.9±42.8 (n=46) 158.5±54.0 (n=33) 155.6±46.0 (n=20) 131.4±65.9 (n=7) 65.3±45.5 (n=18)
Single-flash ERG,
b-wave peak time, ms
31.2±2.0 (n=124) 30.6±1.2 (n=46) 30.8±1.1 (n=33) 31.2±1.1 (n=20) 30.0±2.0 (n=7) 33.1±4.0 (n=18)
30-Hz flicker ERG,
amplitude, μV
61.0±27.3 (n=151) 70.6±24.4 (n=55) 65.9±23.3 (n=45) 62.2±20.9 (n=24) 58.5±23.5 (n=7) 22.9±19.2 (n=20)
30-Hz flicker ERG,
peak time, ms
25.9±3.0 (n=151) 24.6±1.6 (n=55) 25.4±2.1 (n=45) 25.7±1.7 (n=24) 25.6±2.0 (n=7) 30.6±4.5 (n=20)
Central foveal thickness, μm 212.1±30.1 (n=151) 206.2±27.8 (n=55) 215.3±27.9 (n=45) 213.4±31.1 (n=24) 207.7±27.3 (n=7) 221.2±39.3 (n=20)
Mean retinal thickness, μm 265.8±19.0 (n=151) 266.2±15.4 (n=55) 264.3±14.4 (n=45) 268.9±17.6 (n=24) 266.8±57.1 (n=7) 264.5±34.3 (n=20)
Total macular volume, mm3 7.5±0.5 (n=151) 7.5±0.4 (n=55) 7.5±0.4 (n=45) 7.6±0.5 (n=24) 7.5±0.7 (n=7) 7.5±1.0 (n=20)
Fig. 4 Box plot of the mean retinal thickness grouped according to the
level of diabetic retinopathy, excluding laser-treated patients. Box plot
details are as described in Fig. 2
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regions, at least during the first year after treatment [42].
Several studies have demonstrated decreased retinal thickness
with age [43–45]. Similar to what has been found in early
stages of diabetic retinopathy [7], Ooto et al. showed a selec-
tive loss of inner-layer thickness with ageing [44], while Sung
et al. found stable foveal thickness despite general retinal thin-
ning with advancing age [45]. Although direct comparisons of
our data with those of other studies are difficult given the
different population characteristics and the use of different
optical coherence tomography systems, the retinal thickness
parameters were within normal population ranges [46, 47].
Even without age adjustment, we found no significant associ-
ation between retinopathy level and retinal thickness. This
lack of association, coupled with the conflicting results in
the literature, suggests that current SD-OCT capabilities with
regard to clinical staging of diabetic retinopathy are rather
limited, except in the assessment of diabetic macular oedema.
To the best of our knowledge, this is the first study to report
on the relationship between full-field ERG parameters and
changes in retinal thickness as measured by optical coherence
tomography in patients with diabetes. We found a statistically
significant association between mean retinal thickness and the
b-wave amplitude of photopic single-flash and 30-Hz flicker
responses. This was a somewhat unexpected finding, since
there was no clear association between the level of diabetic
retinopathy and any of the retinal thickness parameters.
However, as noted by Oshitari et al. [26], in the early stages
of diabetic retinopathy, thinning of the inner retina may not be
detected by optical coherence tomography measurements be-
cause increased vascular leakage may mask the effects of neu-
ronal degeneration. Thus, while SD-OCT may also reflect
functional loss due to neurodegeneration, its usefulness in
the staging of diabetic retinopathy is limited due to the vascu-
lar hyperpermeability, which probably develops in parallel
with the neurodegenerative process.
Limitations of the study include its cross-sectional design,
the relatively small number of participants with severe non-
proliferative and untreated proliferative retinopathy, and the
lack of a non-diabetic age-matched control group.
Furthermore, only total retinal thickness was measured, and
the level of glycemic control and the presence of combined
systemic diseases were not included in the analyses. One
could also argue that it would be more appropriate to use
multifocal ERG rather than full-field ERG to investigate the
association between functional and morphological parame-
ters, as this technique provides a more detailed mapping of
the central retina and has been shown to correlate with the
development of diabetic retinopathy [48, 49]. On the other
hand, full-field ERG measures the summed response from
the entire retina, and although we have shown that ischemic
Fig. 5 a–d Scatter plots (excluding laser-treated patients) of mean retinal
thickness as a function of a the single-flash b-wave amplitude (r2=0.08,
p=0.006), b the 30-Hz flicker amplitude (r2=0.05, p=0.025), c the
single-flash b-wave peak time (r2=0.002, p=0.724), and d the 30-Hz
flicker peak time (r2=0.03, p=0.068). The fitted regressions are shown
as solid lines
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vascular changes are preferentially located in the posterior
pole and along the vascular arcades [50], the diabetic vascu-
lopathy and neuronal damage may well lead to a generalized
dysfunction of the retina. Moreover, the procedure for
performing full-field ERG is less time-consuming and the
required equipment more readily available and affordable than
for multifocal ERG.
In conclusion, we found no significant association between
the severity of diabetic retinopathy and photopic ERG param-
eters among patients who were naïve to laser treatment. SD-
OCT-derived retinal thickness measurements in the macular
area did not correlate with the severity of retinopathy, but
revealed a significant association with the b-wave amplitude
of photopic single-flash and 30-Hz flicker responses. Given
the wide diversity in the results within each diabetic retinop-
athy level, we believe that both full-field ERG and central
retinal thickness measurements have limited clinical value in
the staging of retinopathy in unselected diabetes patients.
However, thinning of retinal tissue leads to significant func-
tional impairment, and may reflect an ongoing neurodegener-
ative process of the retina. Ideally, diagnostic tools like ERG
and SD-OCT should be able to identify patients who are most
at risk of developing proliferative retinopathy so that closer
follow-up and timely treatment can be offered. This needs to
be explored in larger longitudinal studies, which are clearly
warranted.
Conflict of interest All authors certify that they have no affiliations
with or involvement in any organization or entity with any financial
interest (such as honoraria; educational grants; participation in speakers’
bureaus; membership, employment, consultancies, stock ownership, or
other equity interest; and expert testimony or patent-licensing arrange-
ments), or non-financial interest (such as personal or professional rela-
tionships, affiliations, knowledge or beliefs) in the subject matter or ma-
terials discussed in this manuscript.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prev-
alence of diabetes: estimates for the year 2000 and projections for
2030. Diabetes Care 27:1047–1053
2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1989) The
Wisconsin epidemiological study of diabetic retinopathy. IX. Four-
year incidence and progression of diabetic retinopathy when age of
diagnosis is less than 30 years. Arch Ophthalmol 107:237–243
3. Early Treatment Diabetic Retinopathy Study Research Group
(1991) Early photocoagulation for diabetic retinopathy. ETDRS
report number 9. Ophthalmology 98(suppl 5):766–785
4. Wilkinson CP, Ferris FL, Klein RE et al (2003) Proposed interna-
tional clinical diabetic retinopathy and diabetic macular edema dis-
ease severity scales. Ophthalmology 110:1677–1682
5. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG,
Gardner TW (1998) Neural apoptosis in the retina during experi-
mental and human diabetes. J Clin Invest 102:783–791
6. Abu El-Asrar AM, Dralands L, Missotten L, Al-Jadaan IA, Geboes
K (2004) Expression of apoptosis markers in the retinas of human
subjects with diabetes. Invest Ophthalmol Vis Sci 45:2760–2766
7. van Dijk HW,Kok PH, GarvinM et al (2009) Selective loss of inner
retinal layer thickness in type 1 diabetic patients with minimal dia-
betic retinopathy. Invest Ophthalmol Vis Sci 50:3404–3409
8. Antonetti DA, Klein R, Gardner TW (2012)Diabetic retinopathy. N
Engl J Med 366:1227–1239
9. Scholl HP, Zrenner E (2000) Electrophysiology in the investigation
of acquired retinal disorders. Surv Ophthalmol 45:29–47
10. Marmor MF, Holder GE, Seeliger MW, Yamamoto S, International
Society for Clinical Electrophysiology of Vision (2004) Standard
for clinical electroretinography (2004 update). Doc Ophthalmol
108:107–114
11. Tzekov R, Arden GB (1999) The electroretinogram in diabetic ret-
inopathy. Surv Ophthalmol 44:53–60
12. Yonemura D, Aoki T, Tsuzuki K (1962) Electroretinogram in dia-
betic retinopathy. Arch Ophthalmol 68:19–24
13. GjötterbergM (1974) The electroretinogram in diabetic retinopathy.
A clinical study and a critical survey. Acta Ophthalmol (Copenh)
52:521–533
14. Simonsen SE (1974) Prognostic value of ERG (oscillatory poten-
tial) in juvenile diabetics. Acta Ophthalmol Suppl 123:223–224
15. Bresnick GH, Palta M (1987) Oscillatory potential amplitudes.
Relation to severity of diabetic retinopathy. Arch Ophthalmol
105:929–933
16. Chung NH, Kim SH, Kwak MS (1993) The electroretinogram sen-
sitivity in patients with diabetes. Korean J Ophthalmol 7:43–47
17. Holopigian K, Seiple W, Lorenzo M, Carr R (1992) A Comparison
of photopic and scotopic electroretinographic changes in early dia-
betic retinopathy. Invest Ophthalmol Vis Sci 33:2773–2780
18. Bresnick GH, Palta M (1987) Temporal aspects of the electroreti-
nogram in diabetic retinopathy. Arch Ophthalmol 105:660–664
19. Satoh S, Iijima H, Imai M, Abe K, Shibuya T (1994) Photopic
electroretinogram implicit time in diabetic retinopathy. Jpn J
Ophthalmol 38:178–184
20. Lattanzio R, Brancato R, Pierro L et al (2002) Macular thickness
measured by optical coherence tomography (OCT) in diabetic pa-
tients. Eur J Ophthalmol 12:482–487
21. Sánchez-Tocino H, Alvarez-Vidal A, Maldonado MJ, Moreno-
Montañés J, García-Layana A (2002) Retinal thickness study with
optical coherence tomography in patients with diabetes. Invest
Ophthalmol Vis Sci 43:1588–1594
22. Goebel W, Franke R (2006) Retinal thickness in diabetic retinopa-
thy: comparison of optical coherence tomography, the retinal thick-
ness analyzer, and fundus photography. Retina 26:49–57
23. Sng CC, Cheung CY, Man RE et al (2012) Influence of diabetes on
macular thickness measured using optical coherence tomography:
the Singapore Indian Eye Study. Eye 26:690–698
24. Biallosterski C, van Velthoven ME, Michels RP, Schlingemann
RO, DeVries JH, Verbraak FD (2007) Decreased optical coherence
tomography-measured pericentral retinal thickness in patients with
diabetes mellitus type 1 with minimal diabetic retinopathy. Br J
Ophthalmol 91:1135–1138
25. Asefzadeh B, Fisch BM, Parenteau CE, Cavallerano AA (2008)
Macular thickness and systemic markers for diabetes in individuals
with no or mild diabetic retinopathy. Clin Exp Ophthalmol 36:455–
463
996 Graefes Arch Clin Exp Ophthalmol (2015) 253:989–997
26. Oshitari T, Hanawa K, Adachi-Usami E (2009) Changes of macular
and RNFL thicknesses measured by Stratus OCT in patients with
early stage diabetes. Eye 23:884–889
27. Verma A, Rani PK, Raman R et al (2009) Is neuronal dysfunction
an early sign of diabetic retinopathy? Microperimetry and spectral
domain optical coherence tomography (SD-OCT) study in individ-
uals with diabetes, but no diabetic retinopathy. Eye 23:1824–1830
28. van Dijk HW, Verbraak FD, Kok PH et al (2010) Decreased retinal
ganglion cell layer thickness in patients with type 1 diabetes. Invest
Ophthalmol Vis Sci 51:3660–3665
29. Early Treatment Diabetic Retinopathy Study Research Group
(1991) Grading diabetic retinopathy from stereoscopic color fundus
photographs—an extension of the modified Airlie House classifi-
cation. ETDRS report number 10. Ophthalmology 98:786–806
30. McCulloch DL, Marmor MF, Brigell MG et al (2015) ISCEV
Standard for full-field clinical electroretinography (2015 update).
Doc Ophthalmol 130:1–12
31. Early Treatment Diabetic Retinopathy Study research group (1985)
Photocoagulation for diabetic macular edema. Early Treatment
Diabetic Retinopathy Study report number 1. Arch Ophthalmol
103:1796–1806
32. Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J (2012)
Prevalence of diabetic retinopathy in various ethnic groups: a
worldwide perspective. Surv Ophthalmol 57:347–370
33. Sivaprasad S, Gupta B, Gulliford MC et al (2012) Ethnic variations
in the prevalence of diabetic retinopathy in people with diabetes
attending screening in the United Kingdom (DRIVE UK). PLoS
One 7, e32182
34. Knudsen LL, Lervang HH, Lundbye-Christensen S, Gorst-
Rasmussen A (2006) The North Jutland County Diabetic
Retinopathy Study: population characteristics. Br J Ophthalmol
90:1404–1409
35. Virgili G, Menchini F, Casazza G et al (2015) Optical coherence
tomography (OCT) for detection of macular oedema in patients
with diabetic retinopathy. Cochrane Database Syst Rev. doi:10.
1002/14651858.CD008081.pub3
36. Bernardes R, Serranho P, Lobo C (2011) Digital ocular fundus
imaging: a review. Ophthalmologica 226:161–181
37. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The
Wisconsin epidemiologic study of diabetic retinopathy. II.
Prevalence and risk of diabetic retinopathy when age at diagnosis
is less than 30 years. Arch Ophthalmol 102:520–526
38. Weleber RG (1981) The effect of age on human cone and rod
ganzfeld electroretinograms. Invest Ophthalmol Vis Sci 20:392–
399
39. Wright CE, Williams DE, Drasdo N, Harding GF (1985) The influ-
ence of age on the electroretinogram and visual evoked potential.
Doc Ophthalmol 59:365–384
40. Perlman I, Gdal-OnM,Miller B, Zonis S (1985) Retinal function of
the diabetic retina after argon laser photocoagulation assessed
electroretinographically. Br J Ophthalmol 69:240–246
41. Capoferri C, Bagini M, Chizzoli A, Pece A, Brancato R (1990)
Electroretinographic findings in panretinal photocoagulation for di-
abetic retinopathy. A randomized study with blue-green argon and
red krypton lasers. Graefes Arch Clin Exp Ophthalmol 228:232–
236
42. Kim JJ, Im JC, Shin JP, Kim IT, Park DH (2014) One-year follow-
up of macular ganglion cell layer and peripapillary retinal nerve
fibre layer thickness changes after panretinal photocoagulation. Br
J Ophthalmol 98:213–217
43. Alamouti B, Funk J (2003) Retinal thickness decreases with age: an
OCT study. Br J Ophthalmol 87:899–901
44. Ooto S, Hangai M, Tomidokoro A et al (2011) Effects of age, sex,
and axial length on the three-dimensional profile of normal macular
layer structures. Invest Ophthalmol Vis Sci 52:8769–8779
45. Sung KR, Wollstein G, Bilonick RA et al (2009) Effects of age on
optical coherence tomography measurements of healthy retinal
nerve fiber layer, macula, and optic nerve head. Ophthalmology
116:1119–1124
46. Leung CK, Cheung CY, Weinreb RN et al (2008) Comparison of
macular thickness measurements between time domain and spectral
domain optical coherence tomography. Invest Ophthalmol Vis Sci
49:4893–4897
47. Wexler A, Sand T, Elsås TB (2010) Macular thickness measure-
ments in healthy Norwegian volunteers: an optical coherence to-
mography study. BMC Ophthalmol 10:13
48. Bearse MA Jr, Adams AJ, Han Yet al (2006) A multifocal electro-
retinogram model predicting the development of diabetic retinopa-
thy. Prog Retin Eye Res 25:425–448
49. Lung JC, Swann PG, Wong DS, Chan HH (2012) Global flash
multifocal electroretinogram: early detection of local functional
changes and its correlations with optical coherence tomography
and visual field tests in diabetic eyes. Doc Ophthalmol 125:123–
135
50. Jansson RW, Frøystein T, Krohn J (2012) Topographical distribu-
tion of retinal and optic disc neovascularization in early stages of
proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 53:
8246–8252
Graefes Arch Clin Exp Ophthalmol (2015) 253:989–997 997
